Dusan Ruzic

Dr. Dusan Ruzic

University of Belgrade-Faculty of Pharmacy, Belgrade, Beograd, Serbia
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2020 in Frontiers in Chemistry
Verified
Journal Article
Open access
PDF file
ZGZarko Gagic
Zarko Gagic
Dusan RuzicDusan Ruzic
Dusan Ruzic
NDNemanja Djokovic
Nemanja Djokovic
TDTeodora Djikic
Teodora Djikic
Katarina NikolicKatarina Nikolic
Katarina Nikolic
Rational drug design implies usage of molecular modeling techniques such as pharmacophore modeling, molecular dynamics, virtual screening, and molecular docking to explain the activity of biomolecules, define molecular determinants for interaction with the drug target, and design more efficient drug candidates. Kinases play an essential role in cell function and therefore are extensively studied targets in drug design and discovery. Kinase inhibitors are clinically very important and widely used antineoplastic drugs. In this review, computational methods used in rational drug design of kinase inhibitors are discussed and compared, considering some representative case studies.

16 January 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Dusan RuzicDusan Ruzic
Dusan Ruzic
NDNemanja Djokovic
Nemanja Djokovic
TSTatjana Srdic-Rajic
Tatjana Srdic-Rajic
César A. EcheverríaCésar A. Echeverría
César A. Echeverría
Katarina NikolicKatarina Nikolic
Katarina Nikolic
Juan F. SantibanezJuan F. Santibanez
Juan F. Santibanez
The dysregulation of gene expression is a critical event involved in all steps of tumorigenesis. Aberrant histone and non-histone acetylation modifications of gene expression due to the abnormal activation of histone deacetylases (HDAC) have been reported in hematologic and solid types of cancer. In this sense, the cancer-associated epigenetic alterations are promising targets for anticancer therapy and chemoprevention. HDAC inhibitors (HDACi) induce histone hyperacetylation within target proteins, altering cell cycle and proliferation, cell differentiation, and the regulation of cell death programs. Over the last three decades, an increasing number of synthetic and naturally derived compounds, such as dietary-derived products, have been demonstrated to act as HDACi and have provided biological and molecular insights with regard to the role of HDAC in cancer. The first part of this review is focused on the biological roles of the Zinc-dependent HDAC family in malignant diseases. Accordingly, the small-molecules and natural products such as HDACi are described in terms of cancer therapy and chemoprevention. Furthermore, structural considerations are included to improve the HDACi selectivity and combinatory potential with other specific targeting agents in bifunctional inhibitors and proteolysis targeting chimeras. Additionally, clinical trials that combine HDACi with current therapies are discussed, which may open new avenues in terms of the feasibility of HDACi’s future clinical applications in precision cancer therapies.

24 January 2019 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
LALea Albert
Lea Albert
APAlberto Peñalver
Alberto Peñalver
NDNemanja Djokovic
Nemanja Djokovic
LWLaura Werel
Laura Werel
MHMalte Hoffarth
Malte Hoffarth
OVOlalla Vázquez
Olalla Vázquez

3 November 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MBMilan Beljkas
Milan Beljkas
AIAleksandra Ilic
Aleksandra Ilic
ACAlen Cebzan
Alen Cebzan
BRBranko Radovic
Branko Radovic
NDNemanja Djokovic
Nemanja Djokovic
SOSlavica Oljačić
Slavica Oljačić
Histone deacetylases (HDACs) are the major regulators of the balance of acetylation of histone and non-histone proteins. In contrast to other HDAC isoforms, HDAC6 is mainly involved in maintaining the acetylation balance of many non-histone proteins. Therefore, the overexpression of HDAC6 is associated with tumorigenesis, invasion, migration, survival, apoptosis and growth of various malignancies. As a result, HDAC6 is considered a promising target for cancer treatment. However, none of selective HDAC6 inhibitors are in clinical use, mainly because of the low efficacy and high concentrations used to show anticancer properties, which may lead to off-target effects. Therefore, HDAC6 inhibitors with dual-target capabilities represent a new trend in cancer treatment, aiming to overcome the above problems. In this review, we summarize the advances in tumor treatment with dual-target HDAC6 inhibitors.

6 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
IBIpek Bulut
Ipek Bulut
ALAdam Lee
Adam Lee
BCBuse Cevatemre
Buse Cevatemre
Dusan RuzicDusan Ruzic
Dusan Ruzic
RBRoman Belle
Roman Belle
CACeyda Acilan
Ceyda Acilan
Defects in epigenetic pathways are key drivers of oncogenic cell proliferation. We developed a LSD1/HDAC6 multitargeting inhibitor (iDual), a hydroxamic acid analogue of the clinical candidate LSD1 inhibitor GSK2879552. iDual inhibits both targets with IC50 values of 540, 110, and 290 nM, respectively, against LSD1, HDAC6, and HDAC8. We compared its activity to structurally similar control probes that act by HDAC or LSD1 inhibition alone, as well as an inactive null compound. iDual inhibited the growth of leukemia cell lines at a higher level than GSK2879552 with micromolar IC50 values. Dual engagement with LSD1 and HDAC6 was supported by dose dependent increases in substrate levels, biomarkers, and cellular thermal shift assay. Both histone methylation and acetylation of tubulin were increased, while acetylated histone levels were only mildly affected, indicating selectivity for HDAC6. Downstream gene expression (CD11b, CD86, p21) was also elevated in response to iDual treatment. Remarkably, iDual synergized with doxorubicin, triggering significant levels of apoptosis with a sublethal concentration of the drug. While mechanistic studies did not reveal changes in DNA repair or drug efflux pathways, the expression of AGPAT9, ALOX5, BTG1, HIPK2, IFI44L, and LRP1, previously implicated in doxorubicin sensitivity, was significantly elevated.

25 November 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Dusan RuzicDusan Ruzic
Dusan Ruzic
BEBernhard Ellinger
Bernhard Ellinger
NDNemanja Djokovic
Nemanja Djokovic
Juan F. SantibanezJuan F. Santibanez
Juan F. Santibanez
SGSheraz Gul
Sheraz Gul
Katarina NikolicKatarina Nikolic
Katarina Nikolic
Isoform-selective histone deacetylase (HDAC) inhibition is promoted as a rational strategy to develop safer anti-cancer drugs compared to non-selective HDAC inhibitors. Despite this presumed benefit, considerably more non-selective HDAC inhibitors have undergone clinical trials. In this report, we detail the design and discovery of potent HDAC inhibitors, with 1-benzhydryl piperazine as a surface recognition group, that differ in hydrocarbon linker. In vitro HDAC screening identified two selective HDAC6 inhibitors with nanomolar IC50 values, as well as two non-selective nanomolar HDAC inhibitors. Structure-based molecular modeling was employed to study the influence of linker chemistry of synthesized inhibitors on HDAC6 potency. The breast cancer cell lines (MDA-MB-231 and MCF-7) were used to evaluate compound-mediated in vitro anti-cancer, anti-migratory, and anti-invasive activities. Experiments on the zebrafish MDA-MB-231 xenograft model revealed that a novel non-selective HDAC inhibitor with a seven-carbon-atom linker exhibits potent anti-tumor, anti-metastatic, and anti-angiogenic effects when tested at low micromolar concentrations.